About: The calculation of received dose intensity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The calculation of received dose intensity Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 December 1990

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 1990 (uk) article scientifique publié en 1990 (fr) im Dezember 1990 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'avientu de 1990 (ast) scientific article published on 01 December 1990 (en)
publication date	wds:Q68588440-7AC71598-4EA3-46E9-8747-5B9B5A5269E6
publication date	1990-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q68588440-6E616BC6-19D7-406B-85D8-AEDD5431170A
language of work or name	English
author name string	wds:Q68588440-78DAE4D3-8443-4105-84E6-C029794D3D3D wds:Q68588440-92C99334-5B2E-4A9C-9BC1-AB0D2B976483
author name string	M Goodyear W M Hryniuk
rdfs:label	The calculation of received dose intensity (en) The calculation of received dose intensity (nl)
skos:prefLabel	The calculation of received dose intensity (en) The calculation of received dose intensity (nl)
name	The calculation of received dose intensity (en) The calculation of received dose intensity (nl)
title	wds:Q68588440-9D242842-1D7E-48D4-A501-175D5AF98A82
title	The calculation of received dose intensity (en)
page(s)	wds:Q68588440-DEE519B5-8482-4F01-A6CE-B85A8B6E57F5
page(s)	1935-1937
instance of	wds:Q68588440-86d83144-e383-46cd-ac28-4f9013cf607e wds:Q68588440-DB49073D-9323-45E1-BE12-1C9C7345BFC9
instance of	editorial scholarly article
PubMed ID	wds:Q68588440-56C093ED-FA00-4BA6-860E-DEFF73771BA0
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2230885
PubMed ID	2230885
published in	wds:Q68588440-7637323D-F91D-4ECC-9144-05B33F3AEC71
published in	Journal of Clinical Oncology
issue	wds:Q68588440-8AC12B67-CECF-41DB-9020-A0C49B026383
volume	wds:Q68588440-A373FCAA-F6D2-451C-9C5C-6E04A1C08F84
issue	12
volume	8
DOI	wds:Q68588440-90321F83-9A61-4213-8A67-8CD9E62B320B
DOI	http://dx.doi.org/10.1200/JCO.1990.8.12.1935
DOI	10.1200/JCO.1990.8.12.1935
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q68588440
is cites work of	Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients w Treatment of HIV-associated Kaposi's sarcoma with paclitaxel Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study Curative treatment of gastric cancer: towards a multidisciplinary approach? Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer. Concomitant brain radiotherapy and high-dose ifosfamide in brain relapses of lung cancer. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874] Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel Febrile neutropenic events in cancer patients: treatment for fever and neutropenia in young adult patients during intensive chemotherapy for solid tumours Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Quality of Breast Cancer Treatment at a Rural Cancer Center in Rwanda Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study Calculation of received dose intensity for combinations of drugs using small-cell lung carcinoma treatment regimens as examples Modelling chemotherapy effects on granulopoiesis Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. [Dose intensity received in breast cancer treatment with chemotherapy]
is cites work of	wds:Q35444531-9FD184F7-7F3B-49C5-9428-46EB8B897D8A wds:Q36482438-76BC48E1-26ED-47EF-A13B-99CAD84BDF61

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 194 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software